

해외 바이오의약품 임상 현황 (2020.01.21 ~ 2020.01.26)

한국바이오의약품협회, 2020.1.28.
출처: ClinicalTrials.gov

○ 미국 22건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03605927	CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease	Graft-versus-host-disease[GVHD][GVHD, Acute	Drug: BMS-986004[Drug: Sirolimus][Drug: Tacrolimus	H. Lee Moffitt Cancer Center and Research Institute[Bristol-Myers Squibb	Phase 1 Phase 2
NCT03835728	Efficacy of Ocrelizumab in Autoimmune Encephalitis	Autoimmune Encephalitis	Drug: Ocrelizumab[Drug: Saline	University of Texas Southwestern Medical Center[Genentech, Inc.	Phase 2
NCT03829384	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA-1944 in Healthy Adults.	Prevention of Chikungunya Virus Infection	Biological: mRNA-1944[Other: Placebo	ModernaTX, Inc.	Phase 1
NCT03770455	Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC	Metastatic Castration-resistant Prostate Cancer	Drug: Avelumab[Drug: 2nd generation ADT (abiraterone or enzalutamide)	Jodi Layton, MD[EMD Serono][Tulane University	Phase 2
NCT03747120	Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab	HER2-positive Breast Cancer[Breast Cancer	Drug: Paclitaxel[Drug: Trastuzumab][Drug: Pertuzumab][Drug: Pembrolizumab	Cedars-Sinai Medical Center[Merck Sharp & Dohme Corp.	Phase 2
NCT03691376	NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	HLA-A*0201 Positive Cells Present[HLA-DP4 Positive Cells Present][Platinum-Resistant Ovarian Carcinoma][Recurrent Fallopian Tube Carcinoma][Recurrent Ovarian Carcinoma][Recurrent Primary Peritoneal Carcinoma][Refractory Fallopian Tube Carcinoma][Refractory Ovarian Carcinoma][Refractory Primary Peritoneal Carcinoma	Biological: Aldesleukin[Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes][Other: Cellular Therapy][Drug: Melphalan	Roswell Park Cancer Institute[National Cancer Institute (NCI)	Phase 1
NCT03821246	Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy	Prostate Adenocarcinoma	Drug: Atezolizumab[Drug: Enzalutamide	Lawrence Fong[Genentech, Inc.][University of California, San Francisco	Phase 2
NCT02938442	Vaccination of Triple Negative Breast Cancer Patients	Breast Neoplasms	Biological: P10s-PADRE with MONTANIDE??ISA 51 VG[Drug: Standard Chemotherapy	University of Arkansas	Phase 2
NCT03701321	Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma	Recurrent Plasma Cell Myeloma[Refractory Plasma Cell Myeloma	Drug: Bortezomib[Biological: Daratumumab][Drug: Dexamethasone][Drug: Venetoclax	National Cancer Institute (NCI)	Phase 1 Phase 2
NCT03783936	Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas	Gastric Adenocarcinoma[Esophageal Adenocarcinoma][Metastasis][HER-2 Gene Amplification	Drug: Oxaliplatin[Drug: Leucovorin][Drug: 5 fluorouracil][Drug: Trastuzumab][Drug: Avelumab	Michael Sangmin Lee[EMD Serono][University of North Carolina, Chapel Hill][Hoosier Cancer Research Network	Phase 2
NCT03786770	Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)	Frown Lines	Biological: DaxibotulinumtoxinA for injection	Revance Therapeutics, Inc.	Phase 2
NCT03803202	A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine	Healthy Volunteers[Pneumococcal Disease	Biological: ASP3772[Biological: PCV13][Biological: PPSV23	Astellas Pharma Global Development, Inc.[Affinivax][Astellas Pharma Inc	Phase 1 Phase 2
NCT03761108	First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma	Multiple Myeloma	Drug: REGN5458	Regeneron Pharmaceuticals	Phase 1 Phase 2
NCT03814590	A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults	Respiratory Syncytial Virus Infections	Biological: RSV Vaccine (GSK3844766A) unadjuvanted low dose[Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E][Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B][Biological: RSV Vaccine (GSK3844766A) unadjuvanted medium dose][Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E][Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B][Biological: RSV Vaccine (GSK3844766A) unadjuvanted high dose][Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E][Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B][Drug: Placebo (Saline solution)	GlaxoSmithKline	Phase 1
NCT03761849	A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease	Huntingtons Disease	Drug: RO7234292[Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT03710876	Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma	Malignant Pleural Mesothelioma	Biological: rAd-IFN[Drug: Celecoxib Oral Product][Drug: Gemcitabine	Trizell Ltd[University of Pennsylvania	Phase 3
NCT03626545	Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy	Non-Small-Cell Lung	Drug: Canakinumab[Drug: Docetaxel][Other: Placebo	Novartis Pharmaceuticals[Novartis	Phase 3
NCT03491904	To Assess the Patients' Ability to Self-Administer Fasinumab	Osteoarthritis, Knee[Osteoarthritis, Hip	Drug: Fasinumab A[Drug: Fasinumab PFS	Regeneron Pharmaceuticals[Teva Pharmaceutical Industries, Ltd.	Phase 1
NCT03703167	Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)	Primary Central Nervous System Lymphoma (PCNSL)[Secondary Central Nervous System Lymphoma (SCNSL)	Drug: Ibrutinib[Drug: Lenalidomide][Drug: Rituximab	Memorial Sloan Kettering Cancer Center[Pharmacyclics LLC.	Phase 1
NCT03821233	A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers	HER2-expressing Cancers	Drug: ZW49	Zymeworks Inc.	Phase 1
NCT03731182	A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)	Pneumococcal Infections	Biological: V114[Biological: Pevnar 13??,Merck Sharp & Dohme Corp."	Merck Sharp & Dohme Corp.	Phase 3
NCT03852498	Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)	Cerebral Adrenoleukodystrophy (CALD)	Drug: Genetic	bluebird bio	Phase 3
NCT03806933	Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines	Moderate to Severe Glabellar Frown Lines	Drug: NT 201	Merz Pharmaceuticals GmbH	Phase 2

해외 바이오의약품 임상 현황 (2020.01.21 ~ 2020.01.26)

한국바이오의약품협회, 2020.1.28.
출처: ClinicalTrials.gov

○ 영국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03606512	A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age	Respiratory Syncytial Virus	Biological: Ad26.RSV.preF Biological: Placebo Biological: Nimenrix	Janssen Vaccines & Prevention B.V.	Phase 1 Phase 2
NCT03761849	A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease	Huntingtons Disease	Drug: RO7234292 Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT03710876	Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma	Malignant Pleural Mesothelioma	Biological: rAd-IFN Drug: Celecoxib Oral Product Drug: Gemcitabine	Trizell Ltd University of Pennsylvania	Phase 3
NCT03852498	Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)	Cerebral Adrenoleukodystrophy (CALD)	Drug: Genetic	bluebird bio	Phase 3

○ 프랑스 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03776643	Safety and Efficacy of Low-dose IL-2 in Allergy to Birch Pollen	Allergic Rhinoconjunctivitis to Birch Pollen With an Apple Oral Allergic Syndrome (OAS) to Apple With a Positive Skin Prick Test to Birch Pollen	Drug: ILT-101 Id-(IL2)	Assistance Publique - H ^ô pital de Paris Ilto Pharma	Phase 2
NCT03801304	Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	Drug: Atezolizumab Drug: Vinorelbine	University Hospital, Brest Groupe Français de Pneumo-Cancérologie Roche Farma, S.A Pierre Fabre Medicament	Phase 2
NCT03761849	A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease	Huntingtons Disease	Drug: RO7234292 Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT03710876	Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma	Malignant Pleural Mesothelioma	Biological: rAd-IFN Drug: Celecoxib Oral Product Drug: Gemcitabine	Trizell Ltd University of Pennsylvania	Phase 3
NCT03626545	Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy	Non-Small-Cell Lung	Drug: Canakinumab Drug: Docetaxel Other: Placebo	Novartis Pharmaceuticals Novartis	Phase 3
NCT03852498	Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)	Cerebral Adrenoleukodystrophy (CALD)	Drug: Genetic	bluebird bio	Phase 3

○ 독일 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03520946	RAMucirumab in Combination With TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients	Colorectal Cancer	Drug: Ramucirumab Drug: TAS 102	IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Eli Lilly and Company Trium Analysis Online GmbH	Phase 2
NCT03761849	A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease	Huntingtons Disease	Drug: RO7234292 Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT03626545	Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy	Non-Small-Cell Lung	Drug: Canakinumab Drug: Docetaxel Other: Placebo	Novartis Pharmaceuticals Novartis	Phase 3
NCT03806933	Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines	Moderate to Severe Glabellar Frown Lines	Drug: NT 201	Merz Pharmaceuticals GmbH	Phase 2
NCT03710876	Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma	Malignant Pleural Mesothelioma	Biological: rAd-IFN Drug: Celecoxib Oral Product Drug: Gemcitabine	Trizell Ltd University of Pennsylvania	Phase 3

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03811574	STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity	Overweight Obesity	Drug: Semaglutide Drug: Placebo (semaglutide)	Novo Nordisk A/S	Phase 3
NCT03761849	A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease	Huntingtons Disease	Drug: RO7234292 Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT03626545	Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy	Non-Small-Cell Lung	Drug: Canakinumab Drug: Docetaxel Other: Placebo	Novartis Pharmaceuticals Novartis	Phase 3

해외 바이오의약품 임상 현황 (2020.01.21 ~ 2020.01.26)

한국바이오의약품협회, 2020.1.28.
출처: ClinicalTrials.gov

○ 중국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03827837	Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors	Renal Cell Carcinoma Urothelial Carcinoma Cervical Cancer Ovarian Cancer Recurrent Endometrial Cancer	Biological: SHR-1210 Drug: Famitinib	Jiangsu HengRui Medicine Co., Ltd.	Phase 2
NCT03792347	Combination of Pembrolizumab With Chemoradiation for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma	Esophageal Squamous Cell Carcinoma	Drug: Pembrolizumab	Hecheng Li M.D., Ph.D Ruijin Hospital	Phase 1
NCT03837873	DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma	Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Transformed Lymphoma	Drug: Rituximab Drug: Etoposide Drug: Vincristine Drug: Doxorubicin Drug: Dexamethasone Drug: Cyclophosphamide Drug: Lenalidomide Drug: Cisplatin Drug: Cytarabine	Institute of Hematology & Blood Diseases Hospital	Phase 2
NCT03881111	First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study	Esophageal Neoplasms	Biological: Pembrolizumab Drug: Placebo Drug: Cisplatin Drug: 5-FU	Merck Sharp & Dohme Corp.	Phase 3
NCT03782532	Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma	Asthma	Drug: Dupilumab SAR231893 Drug: Placebo Drug: Asthma Controller Therapies (include prednisone/prednisolone) Drug: Asthma Reliever Therapies	Sanofi Regeneron Pharmaceuticals	Phase 3
NCT03758417	A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma	Multiple Myeloma	Biological: LCAR-B38M CAR-T Cell	Nanjing Legend Biotech Co.,Janssen Research & Development, LLC	Phase 2
NCT03626545	Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy	Non-Small-Cell Lung	Drug: Canakinumab Drug: Docetaxel Other: Placebo	Novartis Pharmaceuticals Novartis	Phase 3